Searle Licenses Beximco’s Remdesivir For Pakistan
Version Of Gilead’s Potential COVID-19 Treatment Already Launched In Bangladesh
Pakistan’s Searle says it has struck a licensing and marketing deal with Bangladesh’s Beximco to market its generic remdesivir in Pakistan as the country grapples with the coronavirus pandemic.
You may also be interested in...
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.
A mixed picture has emerged for Beximco in its financial third quarter as a result of the coronavirus pandemic, with its success launching the first generic of remdesivir balanced by disruption to the supply chain.
Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.